var data={"title":"Furosemide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Furosemide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6244?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=furosemide-drug-information\" class=\"drug drug_general\">see &quot;Furosemide: Drug information&quot;</a> and <a href=\"topic.htm?path=furosemide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Furosemide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7305944\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fluid/electrolyte loss: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Furosemide is a potent diuretic that, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient's needs.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174841\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Lasix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174842\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Furosemide;</li>\n      <li>Bio-Furosemide;</li>\n      <li>Furosemide Injection Sandoz Standard;</li>\n      <li>Furosemide Injection, USP;</li>\n      <li>Furosemide Special;</li>\n      <li>Furosemide Special Injection;</li>\n      <li>Lasix;</li>\n      <li>Lasix Special;</li>\n      <li>PMS-Furosemide;</li>\n      <li>Teva-Furosemide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058876\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihypertensive Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Diuretic, Loop</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442564\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Oral and parenteral (IV, IM)  doses are not interchangeable; due to differences in bioavailability, oral doses are typically higher than IV. Oral solution is available in multiple concentrations (8 mg/mL and 10 mg/mL); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Edema:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Doses of 1 mg/kg/dose 1 to 2 times/day have been used</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: <b>Note:</b> Significant absorption within ECMO circuit; avoid administration directly into circuit; high doses may be required for adequate diuretic effect (Buck 2003):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &lt;31 weeks: 1 mg/kg/dose every 24 hours; accumulation and increased risk of toxicity may be observed with doses &gt;2 mg/kg or doses of 1 mg/kg given more frequently than every 24 hours (Mirochnick 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;31 weeks: 1 to 2 mg/kg/dose every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: 0.2 mg/kg/<b>hour</b>, increase in 0.1 mg/kg/<b>hour</b> increments every 12 to 24 hours to a maximum infusion rate of 0.4 mg/kg/<b>hour</b> (Luciani 1997; Schoemaker 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary edema:</b> Inhalation: 1 to 2 mg/kg/dose diluted in 2 mL NS as a single dose (Brion 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058869\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=furosemide-drug-information\" class=\"drug drug_general\">see &quot;Furosemide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose equivalency for adult patients with normal renal function (approximate): Furosemide 40 mg = bumetanide 1 mg = torsemide 20 mg = ethacrynic acid 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Oral and parenteral (IV, IM) doses are not interchangeable; due to differences in bioavailability, oral doses are typically higher than IV. Oral solution is available in multiple concentrations (8 mg/mL and 10 mg/mL); precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Edema:</b> Infants and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 2 mg/kg once daily; if ineffective, may increase in increments of 1 to 2 mg/kg/dose every 6 to 8 hours; not to exceed 6 mg/kg/dose. In most cases, it is not necessary to exceed individual doses of 4 mg/kg or a dosing frequency of once or twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 1 to 2 mg/kg/dose every 6 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: 0.05 mg/kg/<b>hour</b>; titrate dosage to clinical effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Edema, heart failure:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Initial: 20 to 80 mg/dose with the same dose repeated or increased in increments of 20 to 40 mg/dose at intervals of 6 to 8 hours; usual maintenance dose interval is once or twice daily; may be titrated up to 600 mg/day with severe edematous states. <b>Note:</b> May also be given on 2 to 4 consecutive days every week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 20 to 40 mg/dose; repeat in 1 to 2 hours as needed and increase by 20 mg/dose until the desired effect has been obtained; usual dosing interval: 6 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Initial IV bolus dose of 20 to 40 mg over 1 to 2 minutes, followed by continuous IV infusion doses of 10 to 40 mg/<b>hour</b>. If urine output is &lt;1 mL/kg/<b>hour</b>, increase as necessary to a maximum of 80 to 160 mg/<b>hour</b>. The risk associated with higher infusion rates (80 to 160 mg/<b>hour</b>) must be weighed against alternative strategies. <b>Note:</b> ACC/AHA 2005 guidelines for chronic HF recommend 40 mg IV dose followed by 10 to 40 mg/<b>hour</b> infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute pulmonary edema:</b> IV: 40 mg over 1 to 2 minutes; if response not adequate within 1 hour, may increase dose to 80 mg; <b>Note:</b> ACC/AHA 2005 guidelines for chronic HF recommend a maximum single dose of 160 to 200 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension, resistant</b> (JNC 7): Oral: 20 to 80 mg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Refractory CHF:</b> Oral, IV: Doses up to 8 g/day have been used</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: Acute renal failure: High doses (up to 1 to 3 g/day - oral/IV) have been used to initiate desired response; avoid use in oliguric states</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis: Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic disease:</b> Diminished natriuretic effect with increased sensitivity to hypokalemia and volume depletion in cirrhosis; monitor effects, particularly with high doses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51130589\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no pediatric specific recommendations; in adults with acute renal failure, very high doses may be necessary to initiate diuretic effect; avoid use in oliguric states.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51110602\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">Diminished natriuretic effect with increased sensitivity to hypokalemia and volume depletion in cirrhosis; monitor effects, particularly with high doses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174846\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=furosemide-drug-information\" class=\"drug drug_general\">see &quot;Furosemide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Oral dose equivalency (approximate) for patients with normal renal function (Brater 1983; Cody 1994; Vargo 1995): Furosemide 40 mg = bumetanide 1 mg = ethacrynic acid 50 mg = torsemide 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute pulmonary edema</b>\n      <b>:</b> IV: Initial: 40 mg/dose. If response not adequate within 1 hour, may increase to 80 mg/dose. <b>Note:</b> Minimal additional response is gained by single doses over 160 to 200 mg; maximum: 200 mg/dose (Brater 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Edema:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Initial: 20 to 80 mg/dose; if response is not adequate, may repeat the same dose or increase dose in increments of 20 to 40 mg/dose at intervals of 6 to 8 hours; may titrate up to 600 mg/day with severe edematous states; usual maintenance dose interval is once or twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Heart failure:</i> Initial: 20 to 40 mg once or twice daily; maximum 600 mg/day (ACCF/AHA [Yancy 2013]). <b>Note:</b> Dosing frequency may be adjusted based on patient-specific diuretic needs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV: Initial: 20 to 40 mg/dose; if response is not adequate, may repeat the same dose or increase dose in increments of 20 mg/dose and administer 1 to 2 hours after previous dose (maximum: 200 mg/dose [Brater 1998]). <b>Note:</b> A higher initial dose may be considered for those receiving chronic oral diuretic therapy (the dose of chronic oral therapy may guide the IM/IV dose). Individually determined dose should then be given once or twice daily although some patients may initially require dosing as frequent as every 6 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: Initial: IV bolus dose 40 to 100 mg over 1 to 2 minutes, followed by continuous IV infusion rate of 10 to 40 mg/hour; repeat loading dose before increasing infusion rate (ACCF/AHA [Yancy 2013]); Brater 1998; Howard 2001). <b>Note:</b> In clinical trials evaluating dosing strategies in acute decompensated heart failure, median and maximum doses were &le; 20 mg/hour (Felker 2011; Triposkidadis 2014). With lower baseline CrCl (eg, CrCl &lt;25 mL/minute), the upper end of the initial infusion dosage range should be considered. If urine output is &lt;1 mL/kg/hour, double as necessary to a maximum of 80 to 160 mg/hour (Howard 2001; Schuller 1997). The risk associated with higher infusion rates (80 to 160 mg/hour) must be weighed against alternative strategies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Oral: Initial: 40 mg twice daily; individualize according to patient response and use minimal dose necessary to maintain therapeutic response. If response inadequate, may add another antihypertensive. Usual dosage (ASH/ISH [Weber 2014]): 40 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ascites, due to cirrhosis (off-label dose):</b> Oral: Initial: 40 mg once daily; titrate every 3 to 5 days as clinically indicated (usual maximum: 160 mg once daily); a furosemide to spironolactone dosing ratio of 40 mg (furosemide) to 100 mg (spironolactone) should be maintained (AASLD [Runyon 2012]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990435\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acute renal failure: Doses up to 1 to 3 g daily may be necessary to initiate desired response; avoid use in oliguric states.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis: Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987620\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">Diminished natriuretic effect with increased sensitivity to hypokalemia and volume depletion in cirrhosis. Monitor effects, particularly with high doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174813\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (2 mL, 4 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (2 mL, 4 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/100 mL in NaCl 0.9% (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 8 mg/mL (5 mL [DSC], 500 mL); 10 mg/mL (60 mL, 120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lasix: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lasix: 40 mg, 80 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 40 mg, 80 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174798\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058880\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: May administer with food or milk to decrease GI distress </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: IV: May be administered undiluted direct IV at a maximum rate of 0.5 mg/kg/minute (not to exceed 4 mg/minute); may also be diluted and infused over 10 to 15 minutes (following maximum rate as above); in adults, 20 to 40 mg undiluted solution may be administered over 1 to 2 minutes </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472641\" class=\"block uicn drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 2 mg/mL <b>or</b> undiluted as 10 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472640\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 1 mg/mL <b>or</b> 2 mg/mL <b>or</b> undiluted as 10 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174834\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Store at room temperature. Protect from light. Exposure to light may cause discoloration; do not use furosemide solutions if they have a yellow color. Furosemide solutions are unstable in acidic media, but very stable in basic media. Refrigeration may result in precipitation or crystallization; however, resolubilization at room temperature or warming may be performed without affecting the drug's stability. Infusion solution in D5W, NS, or LR is stable for 24 hours at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, solution: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 89&deg;F). Protect from light. Discard opened bottle of solution after 90 days (10 mg/mL concentration only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058879\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of edema associated with heart failure and hepatic or renal disease; used alone or in combination with antihypertensives in treatment of hypertension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174902\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Furosemide may be confused with famotidine, finasteride, fluconazole, FLUoxetine, fosinopril, loperamide, torsemide</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lasix may be confused with Lanoxin, Lidex, Lomotil, Lovenox, Luvox, Luxiq</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Diuretics are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lasix [US, Canada, and multiple international markets] may be confused with Esidrex brand name for hydrochlorothiazide [multiple international markets]; Esidrix brand name for hydrochlorothiazide [Germany]; Losec brand name for omeprazole [multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Urex [Australia, Hong Kong, Turkey] may be confused with Eurax brand name for crotamiton [US, Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174899\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Necrotizing angiitis, orthostatic hypotension, thrombophlebitis, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache, paresthesia, restlessness, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acute generalized exanthematous pustulosis, bullous pemphigoid, erythema multiforme, exfoliative dermatitis, pruritus, skin photosensitivity, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Glycosuria, hyperglycemia, hyperuricemia, increased serum cholesterol, increased serum triglycerides</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea, gastric irritation, mouth irritation, nausea, pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Bladder spasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, aplastic anemia, eosinophilia, hemolytic anemia, leukopenia, purpura, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic encephalopathy, intrahepatic cholestatic jaundice, liver enzymes increased</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, anaphylactoid reaction, anaphylactic shock</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: DRESS syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site (following IM injection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Muscle spasm, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, xanthopsia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Deafness, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Interstitial nephritis (allergic), renal disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174820\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to furosemide or any component of the formulation; anuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to sulfonamide-derived drugs; complete renal shutdown; hepatic coma and precoma; uncorrected states of electrolyte depletion, hypovolemia, dehydration, or hypotension; jaundiced newborn infants or infants with disease(s) capable of causing hyperbilirubinemia and possibly kernicterus; breast-feeding. <b>Note:</b> Manufacturer labeling for Lasix Special and Furosemide Special Injection also includes: GFR &lt;5 mL/minute or GFR &gt;20 mL/minute; hepatic cirrhosis; renal failure accompanied by hepatic coma and precoma; renal failure due to poisoning with nephrotoxic or hepatotoxic substances.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Although the approved product labeling states this medication is contraindicated with other sulfonamide-containing drug classes, the scientific basis of this statement has been challenged. See &ldquo;Warnings/Precautions&rdquo; for more detail.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174802\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid/electrolyte loss: <b>[US Boxed Warning]: If given in excessive amounts, furosemide, similar to other loop diuretics, can lead to profound diuresis, resulting in fluid and electrolyte depletion.</b> Close medical supervision and dose evaluation are required. Watch for and correct electrolyte disturbances; adjust dose to avoid dehydration. When electrolyte depletion is present, therapy should not be initiated unless serum electrolytes, especially potassium, are normalized. Risk of hypokalemia may be increased by: rapid diuresis, poor oral potassium intake, cirrhosis, and combined use with large amounts of licorice, corticosteroids, or laxatives (chronic use). In contrast to thiazide diuretics, a loop diuretic can also lower serum calcium concentrations. Electrolyte disturbances can predispose a patient to serious cardiac arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperuricemia: Asymptomatic hyperuricemia has been reported with use; rarely, may precipitate gout.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: Monitor fluid status and renal function in an attempt to prevent oliguria, azotemia, and reversible increases in BUN and creatinine; close medical supervision of aggressive diuresis required. May increase risk of radiocontrast-induced nephropathy in high-risk patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ototoxicity: Rapid IV administration, severe renal impairment, excessive doses, hypoproteinemia, and concurrent use of other ototoxins is associated with ototoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Photosensitization may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfonamide (&ldquo;sulfa&rdquo;) allergy: The approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid effects: Doses &gt;80 mg may result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal insufficiency: Avoid use of diuretics for treatment of elevated blood pressure in patients with primary adrenal insufficiency (Addison disease). Adjustment of glucocorticoid/mineralocorticoid therapy and/or use of other antihypertensive agents is preferred to treat hypertension (Bornstein 2016; Inder 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cirrhosis: In cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy; correct electrolyte and acid/base imbalances prior to initiation when hepatic coma is present. Supplemental potassium or an aldosterone antagonist, when appropriate, may reduce risk of hypokalemia and metabolic alkalosis. Close monitoring warranted, especially with initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: May cause urinary retention due to increased urine production, especially upon initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic lupus erythematosus (SLE): May cause SLE exacerbation or activation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May lead to nephrocalcinosis or nephrolithiasis in premature infants or in children &lt;4 years of age with chronic use. May prevent closure of patent ductus arteriosus in premature infants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: If given the morning of surgery, furosemide may render the patient volume depleted and blood pressure may be labile during general anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings and precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diuretic resistance:  For some patients, despite higher doses of loop diuretic treatment, an adequate diuretic response cannot be attained. Diuretic resistance can usually be overcome by intravenous administration, the use of two diuretics together (eg, furosemide and chlorothiazide), or the use of a diuretic with a positive inotropic agent. When such combinations are used, serum electrolytes need to be monitored even more closely (ACC/AHA [Yancy 2013]; Cody 1994; HFSA 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299370\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OAT3; <b>Inhibits</b> MRP2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174807\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13329&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the therapeutic effect of Furosemide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: May decrease the serum concentration of Furosemide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically, Loop Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Loop Diuretics may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: Loop Diuretics may enhance the QTc-prolonging effect of Bilastine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Loop Diuretics.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canagliflozin: May enhance the hypotensive effect of Loop Diuretics. Management: If canagliflozin is combined with a loop diuretic, monitor for symptoms of intravascular volume depletion and hypotension. Canadian product labeling recommends avoiding the combination of canagliflozin and loop diuretics.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Loop Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of loop diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefotiam: Loop Diuretics may enhance the nephrotoxic effect of Cefotiam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpirome: Loop Diuretics may enhance the nephrotoxic effect of Cefpirome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceftizoxime: Loop Diuretics may enhance the nephrotoxic effect of Ceftizoxime. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Loop Diuretics may enhance the nephrotoxic effect of Cephalothin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephradine: May enhance the nephrotoxic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: Furosemide may enhance the adverse/toxic effect of Chloral Betaine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Hydrate: Furosemide may enhance the adverse/toxic effect of Chloral Hydrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CISplatin: Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Loop Diuretics may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: Loop Diuretics may enhance the QTc-prolonging effect of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Empagliflozin: May enhance the hypotensive effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethacrynic Acid: Furosemide may enhance the ototoxic effect of Ethacrynic Acid. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: Loop Diuretics may increase the serum concentration of Foscarnet. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May diminish the diuretic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipragliflozin: May enhance the adverse/toxic effect of Loop Diuretics. Specifically, the risk for intravascular volume depletion may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Loop Diuretics may enhance the arrhythmogenic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Loop Diuretics may enhance the adverse/toxic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Licorice: May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Loop Diuretics may decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May diminish the therapeutic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate. Methotrexate may increase the serum concentration of Loop Diuretics. Management: Monitor for increased methotrexate and/or loop diuretic levels/toxicity with concomitant use of these agents and monitor for decreased therapeutic effects of loop diuretics. Methotrexate and/or loop diuretic dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Loop Diuretics may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May diminish the diuretic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics. Management: Monitor for decreased diuretic effects or increased adverse effects of loop diuretics with concomitant use of probenecid. Bumetanide prescribing information recommends against concomitant use of probenecid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: Loop Diuretics may enhance the QTc-prolonging effect of Promazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reboxetine: May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RisperiDONE: Loop Diuretics may enhance the adverse/toxic effect of RisperiDONE.  Management: Consider alternative diuretic therapy (e.g., thiazides) to more potent diuretics (e.g., furosemide) in elderly patients receiving risperidone. Patients who require use of more potent diuretic therapy should be closely monitored and adequately hydrated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the serum concentration of Furosemide. Sucralfate may impair the absorption of furosemide. Management: Avoid concomitant oral administration of furosemide and sucralfate. Separate administration by at least 2 hours. Does not apply to parenterally administered furosemide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tobramycin (Oral Inhalation): Loop Diuretics may enhance the nephrotoxic effect of Tobramycin (Oral Inhalation). Loop Diuretics may enhance the ototoxic effect of Tobramycin (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Loop Diuretics may enhance the hypokalemic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the adverse/toxic effect of Loop Diuretics. Specifically, the risk of hypovolemia, electrolyte disturbances, and prerenal azotemia may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174837\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Furosemide serum levels may be decreased if taken with food. Management: Administer on an empty stomach.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174809\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174823\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events  have been observed in animal reproduction studies. Furosemide crosses the placenta (Riva 1978). Furosemide has been used to treat heart failure in pregnant women (ESC 2011; Johnson-Coyle 2012).  Monitor fetal growth if used during pregnancy; may increase birth weight. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058875\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum electrolytes, renal function, blood pressure, hearing (if high dosages used)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174801\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits reabsorption of sodium and chloride in the ascending loop of Henle and proximal and distal renal tubules, interfering with the chloride-binding cotransport system, thus causing increased excretion of water, sodium, chloride, magnesium, and calcium</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174819\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Diuresis: Oral, sublingual (SL): 30 to 60 minutes; IM: 30 minutes; IV: ~5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symptomatic improvement with acute pulmonary edema: Within 15 to 20 minutes; occurs prior to diuretic effect</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Oral, SL: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Oral, SL: 6 to 8 hours; IV: 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 91% to 99%; primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minimally hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral tablet: 47% to 64%; Oral solution: 50%; SL administration of oral tablet: ~60%; results of a small comparative study (n=11) showed bioavailability of SL administration of tablet was ~12% higher than oral administration of tablet (Haegeli 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Normal renal function: 0.5 to 2 hours; End-stage renal disease (ESRD): 9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (Oral: 50%, IV: 80%) within 24 hours; feces (as unchanged drug); nonrenal clearance prolonged in renal impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174822\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Furosemide in Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 0.9% (100 mL): $42.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Furosemide Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (10 mL): $4.23</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Furosemide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg/mL (500 mL): $48.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (60 mL): $10.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Furosemide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $14.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $16.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (100): $43.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Lasix Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $71.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $100.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (50): $81.08</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174826\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>A Xi Ya (CN);</li>\n      <li>A-Basedock (JP);</li>\n      <li>Accent (JP);</li>\n      <li>Ai Ge (CN);</li>\n      <li>Akoset (MY);</li>\n      <li>Anfuramide (JP);</li>\n      <li>Aquarid (ZA);</li>\n      <li>Aquasin (ZW);</li>\n      <li>Arasemide (JP);</li>\n      <li>Bondiur (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Busemida (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Dailix (KR);</li>\n      <li>Daiteren F (JP);</li>\n      <li>Depix (JP);</li>\n      <li>Desal (PL);</li>\n      <li>Dirine (MY);</li>\n      <li>Disemide (TW);</li>\n      <li>Diural (DK, NO, SE);</li>\n      <li>Diuren (ZW);</li>\n      <li>Diuresal (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Diurin (NZ);</li>\n      <li>Diurmessel (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Diusemide (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Diuvar (ID);</li>\n      <li>Edemid (HR);</li>\n      <li>Edemin (ID);</li>\n      <li>Errolon (AR);</li>\n      <li>Femide 500 (TH);</li>\n      <li>Foliront (JP);</li>\n      <li>Fretic (PH);</li>\n      <li>Frusedan (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Frusema (PH);</li>\n      <li>Frusid (HK, NZ);</li>\n      <li>Fruside (IE, ZW);</li>\n      <li>Frusovit (LK);</li>\n      <li>Fulsix (JP);</li>\n      <li>Fuluvamide (JP);</li>\n      <li>Furanthril (CZ);</li>\n      <li>Furanturil (BG);</li>\n      <li>Furetic (TH);</li>\n      <li>Furide (TW);</li>\n      <li>Furix (NO, SE);</li>\n      <li>Furo-Puren (DE);</li>\n      <li>Furomen (FI);</li>\n      <li>Furomex (CZ);</li>\n      <li>Furomin (FI);</li>\n      <li>Furon (HU);</li>\n      <li>Furorese (DE, LU);</li>\n      <li>Furosan (VN);</li>\n      <li>Furose (PH);</li>\n      <li>Furosedon (JP);</li>\n      <li>Furosemid (HR, HU);</li>\n      <li>Furosemid Pharmavit (HU);</li>\n      <li>Furosemid-ratiopharm (LU);</li>\n      <li>Furosemide-Eurogenerics (LU);</li>\n      <li>Furosemix (LU);</li>\n      <li>Furosetic (LB);</li>\n      <li>Furosix (BR);</li>\n      <li>Furovenir (IL);</li>\n      <li>Fursemid (HR);</li>\n      <li>Fursemid[inj.] (HR);</li>\n      <li>Furusemide (JP);</li>\n      <li>Fuseride (TH);</li>\n      <li>Fusid (DE, IL);</li>\n      <li>Fusimex (PH);</li>\n      <li>Glosix (ID);</li>\n      <li>Impugan (DK, ID, SE);</li>\n      <li>Indiurex (PH);</li>\n      <li>Jufurix (DE);</li>\n      <li>Katlex (JP);</li>\n      <li>Kutrix (JP);</li>\n      <li>Lasilix (FR, MA, MT);</li>\n      <li>Lasix (AE, AT, AU, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EG, ET, FI, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, ID, IE, IN, IQ, IR, IT, JM, JO, KE, KR, KW, LB, LK, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PK, PR, PT, PY, QA, RU, SA, SC, SD, SE, SG, SI, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, VN, YE, ZM, ZW);</li>\n      <li>Lasix Retard (DK, EE, IS, LT, NO, PT, SE);</li>\n      <li>Lasix[inj.] (HR);</li>\n      <li>Laveric (ID);</li>\n      <li>Lazyks (UA);</li>\n      <li>Lowpston (JP);</li>\n      <li>Luseck (JP);</li>\n      <li>Maoread (JP);</li>\n      <li>Naclex (ID);</li>\n      <li>Nadis (TW);</li>\n      <li>Nephron (AR);</li>\n      <li>Odemase (DE);</li>\n      <li>Odemex (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Oedemex (AE, BH, CH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Pharmix (PH);</li>\n      <li>Promedes (JP);</li>\n      <li>Radisemide (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Radouna (JP);</li>\n      <li>Rasitol (MY, PH, SG, TW);</li>\n      <li>Releef (TZ);</li>\n      <li>Retep (AR);</li>\n      <li>Rosemide (PH);</li>\n      <li>Rosis (TW);</li>\n      <li>Roxemid (ID);</li>\n      <li>Salinex (IN);</li>\n      <li>Salurex (MT);</li>\n      <li>Salurin (AE, KW, QA, SA);</li>\n      <li>Seguril (ES);</li>\n      <li>Silax (ID);</li>\n      <li>Solax (PY);</li>\n      <li>Synephron (JP);</li>\n      <li>Trofurit (HU);</li>\n      <li>Uremide (AU, NZ);</li>\n      <li>Uresix (ID);</li>\n      <li>Urex (AU, HK, JP);</li>\n      <li>Urex Forte (HK);</li>\n      <li>Urex-M (AU);</li>\n      <li>Urimeg (PY);</li>\n      <li>Urinal (BH, JO);</li>\n      <li>Usix (VN);</li>\n      <li>Vusimide (MY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aufricht C, Votava F, Marx M, et al, &quot;Intratracheal Furosemide in Infants After Cardiac Surgery: Its Effects on Lung Mechanics and Urinary Output, and Its Levels in Plasma and Tracheal Aspirate,&quot; <i>Intensive Care Med</i>, 1997, 23(9):992-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/9347373/pubmed\" target=\"_blank\" id=\"9347373\">9347373</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brion LP, Primhak RA, and Yong W, &quot;Aerosolized Diuretics for Preterm Infants With (or Developing) Chronic Lung Disease,&quot; <i>Cochrane Database Syst Rev</i>, 2006, 3:CD001694.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/16855973/pubmed\" target=\"_blank\" id=\"16855973\">16855973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buck ML, &quot;Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation: Implications for Drug Therapy of Neonates,&quot; <i>Clin Pharmacokinet</i>, 2003, 42(5):403-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/12739981/pubmed\" target=\"_blank\" id=\"12739981\">12739981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo; <i>JAMA</i>, 2003, 289(19):2560-72. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/12748199/pubmed\" target=\"_blank\" id=\"12748199\">12748199</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cody RJ, Kubo SH, and Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. <i>Arch Intern Med</i>. 1994;154(17):1905-1914. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/8074594/pubmed\" target=\"_blank\" id=\"8074594\">8074594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Copeland JG, Campbell DW, Plachetka JR, et al, &ldquo;Diuresis With Continuous Infusion of Furosemide After Cardiac Surgery,&rdquo; <i>Am J Surg</i>, 1983, 146(6):796-9. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/6650766/pubmed\" target=\"_blank\" id=\"6650766\">6650766</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Engle MA, Lewy JE, Lewy PR, et al, &quot;The Use of Furosemide in the Treatment of Edema in Infants and Children,&quot; <i>Pediatrics</i>, 1978, 62(5):811-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/724325/pubmed\" target=\"_blank\" id=\"724325\">724325</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Society of Gynecology (ESG). ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2011;32(24):3147-3197.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunt SA, Abraham WT, Chin MH, et al, &quot;ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure),&quot; <i>J Am Coll Cardiol</i>, 2005, 46(6):1116-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/16168273 /pubmed\" target=\"_blank\" id=\"16168273 \">16168273 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP), &quot;Standard Concentrations of Neonatal Drug Infusions,&quot; <i>ISMP</i>, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson-Coyle L, Jensen L, Sobey A, et al. Peripartum cardiomyopathy: review and practice guidelines. <i>Am J Crit Care</i>. 2012;21(2):89-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/22381985 /pubmed\" target=\"_blank\" id=\"22381985 \">22381985 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo; <i>J Card Fail</i>, 2010, 16(6):e1-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luciani GB, Nichani S, Chang AC, et al, &quot;Continuous Versus Intermittent Furosemide Infusion in Critically Ill Infants After Open Heart Operations,&quot; <i>Ann Thorac Surg</i>, 1997, 64(4):1133-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/9354540/pubmed\" target=\"_blank\" id=\"9354540\">9354540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirochnick MH, Miceli JJ, Kramer PA, et al, &quot;Furosemide Pharmacokinetics in Very Low Birth Weight Infants,&quot; <i>J Pediatr</i>, 1988, 112(4):653-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/3351693/pubmed\" target=\"_blank\" id=\"3351693\">3351693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pai VB and Nahata MC, &ldquo;Aerosolized Furosemide in the Treatment of Acute Respiratory Distress and Possible Bronchopulmonary Dysplasia in Preterm Neonates,&rdquo; <i>Ann Pharmacother</i>, 2000, 34(3):386-92. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/ 10917388 /pubmed\" target=\"_blank\" id=\" 10917388 \"> 10917388 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prandota J, &quot;Clinical Pharmacology of Furosemide in Children: A Supplement,&quot; <i>Am J Ther</i>, 2001, 8(4):275-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/11441327/pubmed\" target=\"_blank\" id=\"11441327\">11441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rastogi A, Luayon M, Ajayi OA, et al, &ldquo;Nebulized Furosemide in Infants With Bronchopulmonary Dysplasia,&rdquo; <i>J Pediatr</i>, 1994, 125(6 Pt 1):976-9. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/ 7996373 /pubmed\" target=\"_blank\" id=\" 7996373 \"> 7996373 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riva E, Farina P, Tognoni G, Bottino S, Orrico C, Pardi G. Pharmacokinetics of furosemide in gestosis of pregnancy. <i>Eur J Clin Pharmacol</i>. 1978;14(5):361-366.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/729629 /pubmed\" target=\"_blank\" id=\"729629 \">729629 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rudy DW, Voelker JR, Greene PK, et al, &ldquo;Loop Diuretics for Chronic Renal Insufficiency: A Continuous Infusion Is More Efficacious Than Bolus Therapy,&rdquo; <i>Ann Intern Med</i>, 1991, 115(5):360-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/1863026/pubmed\" target=\"_blank\" id=\"1863026\">1863026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schoemaker RC, van dDer Vorst MM, van Heel IR, et al, &quot;Development of an Optimal Furosemide Infusion Strategy in Infants With Modeling and Simulation,&quot; <i>Clin Pharmacol Ther</i>, 2002, 72(4):383-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/12386640/pubmed\" target=\"_blank\" id=\"12386640\">12386640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/furosemide-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13329 Version 252.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F7305944\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F174841\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F174842\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058876\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442564\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1058869\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51130589\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51110602\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F174846\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990435\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987620\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F174813\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F174798\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058880\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Neonatal\" href=\"#F14472641\" class=\"outlineLink\">Usual Infusion Concentrations: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472640\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F174834\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058879\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F174902\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F174899\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F174820\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F174802\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299370\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F174807\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F174837\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F174809\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F174823\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058875\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F174801\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F174819\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F174822\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F174826\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13329|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=furosemide-drug-information\" class=\"drug drug_general\">Furosemide: Drug information</a></li><li><a href=\"topic.htm?path=furosemide-patient-drug-information\" class=\"drug drug_patient\">Furosemide: Patient drug information</a></li></ul></div></div>","javascript":null}